On February 2, 2026, President Trump posted on Truth Social. Prime Minister Modi called it a "wonderful announcement." In a single phone call, the effective tariff on Indian goods entering the United States — which had climbed as high as 50% just months earlier — was slashed to 18%. The Gift Nifty surged 600 points before markets even opened. Textile stocks hit upper circuits. Pharma stocks rallied. And investors across India suddenly needed to understand what this means for their portfolios.
This article is that guide. We cover the full tariff timeline, which sectors benefit and which face headwinds, where the BTA stands now in April 2026, and the only thing that actually matters for retail investors: what should your SIPs and portfolio do?
"In twelve months, the same US tariff on Indian goods went 26% → 50% → 18%. The investor who panicked at 50% sold at the bottom. The investor who understood the negotiating dynamics held on — and is now looking at a structural tailwind."
The Full Tariff Timeline: How We Got Here
Understanding where we are today requires knowing the full journey — because this deal did not come out of nowhere. It came after over a year of escalating pressure, retaliation threats, and diplomatic back-channel work.
| Date | Event | Effective US Tariff on India |
|---|---|---|
| April 2025 | Trump announces "reciprocal tariff" on India | 26% |
| April–Aug 2025 | 90-day pause for most countries; India-US talks begin | 26% (paused, then reinstated) |
| August 2025 | US adds 25% punitive tariff (Russia oil purchases) | ~50% effective |
| Aug–Jan 2026 | Intense negotiations; India offers energy + farm concessions | ~50% |
| Feb 2, 2026 | Modi-Trump call — interim deal agreed | 18% |
| Feb 8, 2026 | White House Executive Order signed; 25% punitive tariff removed | 18% |
| April 2026 | BTA Tranche 1 implementation expected now | 18% + deeper BTA framework in progress |
The deal was not one-sided. India committed to: (1) stop purchasing Russian Federation oil, (2) commit to buying $500 billion+ of US energy, technology, agricultural, and coal products, and (3) reduce or eliminate tariffs on US industrial goods and agricultural products under the BTA. This matters for investors because domestic agriculture and energy sectors face some headwinds from this arrangement.
Sector Winners: Who Benefits Most
The 18% tariff rate is not equally impactful across all sectors. The biggest winners are those with heavy direct US export dependence — where the 50% tariff had caused real pricing damage against competitors from Vietnam, Bangladesh, and China.
Textiles & Apparel
32% of India's textile exports go to the US. The tariff drop directly restores pricing competitiveness vs. Bangladesh and Vietnam. Gokaldas Exports surged up to 20%, KPR Mill +10%, Arvind +7%, Vardhman +8%, Welspun Living +3%, Raymond Lifestyle +5% on deal day. Stocks are still below pre-tariff peaks — the re-rating is not done.
Pharma & Chemicals
The US is the single largest market for Indian generic drugs. Tariff relief improves pricing power and margin on active pharmaceutical ingredients (APIs). Nifty Pharma rose 3%+ post-deal. Companies like Sun Pharma, Dr. Reddy's, Cipla, and Divi's Labs are direct beneficiaries as US procurement continues to favour lower-cost Indian generics.
IT & Tech Services
IT services are not tariffed (services ≠ goods). But the IT sector had fallen 10–12% during the tariff escalation period on fears of US GDP slowdown cutting client budgets. The deal restores US business confidence, reduces recession risk, and is a sentiment tailwind for TCS, Infosys, Wipro, HCL, and Tech Mahindra.
Gems, Jewellery & Engineering
India is one of the world's largest gems and jewellery exporters — the US is a key market. Tariff relief restores competitiveness vs. other exporters. Engineering goods (precision parts, auto components) also benefit from improved cost competitiveness, especially as US manufacturers seek to de-risk supply chains away from China.
Sectors Facing Headwinds: The Other Side of the Deal
Every trade deal has two sides. India gave meaningful concessions to secure the 18% rate, and some domestic sectors now face increased competition or structural cost shifts.
| Sector | Headwind | Investor Implication |
|---|---|---|
| Agriculture (Domestic) | India agreed to reduce barriers on US farm goods — wheat, pulses, dairy, soy | Domestic agri commodity prices under pressure; rural FMCG and fertiliser sectors to watch |
| Oil & Refining | India committed to stop buying discounted Russian oil; switches to higher-priced US/Middle East crude | Input cost rise for refiners (HPCL, BPCL, IOC); petrol/diesel price pressure may return |
| Domestic Manufacturers | US industrial goods get tariff reductions in India under BTA — competing with domestic output | Sector-specific; watch capital goods and electronics where US exports are significant |
| IT (Indirect Risk) | If US GDP slows despite deal (tariffs still 18%, not zero), client budgets remain cautious | Analysts estimate 2–3% FY27 revenue impact for Tier-1 IT if US GDP falls 0.5% |
The 18% rate is part of an interim trade framework, not the complete Bilateral Trade Agreement (BTA). Commerce Minister Piyush Goyal confirmed in February that the first BTA tranche would be operationalised by April 2026 — which is now. A more comprehensive formal agreement was targeted for mid-March but is still being negotiated. Until the full BTA is signed, the 18% rate is subject to political and negotiating dynamics on both sides. Investors should treat the current situation as "improved but not finalised."
What the Market Has Already Priced In
Here is the key question for investors in April 2026: if the deal was announced in February, has the market already moved? Partially yes — but not fully. The immediate rally (Gift Nifty +600 points, textile stocks +7–20%) priced in the announcement. But the full re-rating of export sectors depends on actual order flows, not just tariff rates, and those take 2–3 quarters to materialise in earnings.
| Asset / Index | Reaction at Announcement | Status April 2026 |
|---|---|---|
| Gift Nifty | +600 pts same day | Partially priced in; Nifty recovering from Feb lows |
| Nifty IT Index | Positive sentiment; expected rally | Still down ~10–17% from 52-week highs (TCS, Infosys pressured by earnings) |
| Textile Stocks | +7% to +20% at announcement | In-week gains up to 40%; further upside as order inflows build |
| Nifty Pharma | +3%+ post deal | Positive momentum; US generics pricing competitive again |
| BTA Tranche 1 | Not yet priced (pending) | April 2026 operationalisation = next catalyst |
What Should Your SIPs Do? A Practical Framework
Most retail investors are invested through diversified mutual funds, not individual stocks. So the real question is not "should I buy Gokaldas Exports?" — it is "how does this trade deal affect my existing SIPs, and should I make any changes?" The answer depends on what you hold.
Do nothing different — but review your fund's sector weights. Most large-cap and flexi-cap funds already have meaningful IT exposure (15–25%) and growing pharma exposure (5–10%). The deal is a tailwind for both. The fund manager will naturally tilt toward beneficiary sectors over the next 1–2 quarters as earnings improve. Your job is simply to keep the SIP running consistently through the volatility.
Consider a dedicated sector or thematic fund. Pharma and export-oriented textile/manufacturing funds directly capture the trade deal tailwind. But approach with eyes open: sectoral funds are concentrated bets, not diversified vehicles. If you add a sectoral fund, keep it to 10–15% of your total equity portfolio, not more. And use SIP mode — not a lump sum — given the near-term volatility that remains.
Your Investor Action Plan
🌟 5 Steps to Position for the India-US Trade Deal
The India-US tariff story is far from over. The BTA is still being negotiated. The 18% rate is an interim number. And geopolitical shifts can move tariffs again — as we saw in 2025 when they went from 26% to 50% in a matter of months. What does not change is the structural case for Indian exports: cost competitiveness, scale, and now, a improving trade relationship with the world's largest economy. That tailwind is worth investing in — patiently, not impulsively.